There is a lot that we learned from BOSTON, and there’s a lot that we’re still learning. There was a time where bortezomib was intravenous twice weekly. Now…it’s once weekly subcutaneous, and ...
Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later ...
Eli Lilly has seen revenue and earnings soar in recent years.
Menopause is expected to cause symptoms in about 80% of patients. These can vary from mild to very severe and debilitating. The most common are collectively termed vasomotor symptoms (VMS), including ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsAndrew Guggenhime - President & CFOGrant Pickering ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Q4 2025 Management View Randy Teel, CEO, stated the company is entering a period with "multiple value-driving milestones," highlighting Arvinas' first new drug application submission, which may lead ...
Children with multiple nut allergies experienced significant increases in the amounts of allergens they could tolerate with oral immunotherapy using very low doses, according to data published in ...
Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...
Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...
For the first study, published yesterday in eClinicalMedicine, an international roster of researchers in the INTERCOVID consortium mined data from 6,527 pregnant women with and without a COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results